- Recruiting
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
Updated: Sep 16, 2022
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
Newly Diagnosed Multiple Myeloma
Relapsed Refractory Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
Sponsor
Janssen Research & Development, LLC
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04722146
Official Title: A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
First Posted : January 25, 2021
Click here for details on ClinicalTrials.gov